	US 11,912,777 B2
	Antibodies binding TNFR2 and uses thereof
Xiaoqiang Kang, Plainsboro, NJ (US); Shoupeng Lai, Germantown, MD (US); Xiao Huang, Jiangsu (CN); Huan Lin, Jiangsu (CN); and Yujia Dang, Jiangsu (CN)
Assigned to Nanjing Leads Biolabs Co., Ltd., Nanjing (CN)
Filed by Nanjing Leads Biolabs Co., Ltd., Jiangsu (CN)
Filed on Dec. 9, 2022, as Appl. No. 18/064,061.
Application 18/064,061 is a continuation of application No. PCT/CN2021/099732, filed on Jun. 11, 2021.
Claims priority of application No. PCT/CN2020/095933 (WO), filed on Jun. 12, 2020.
Prior Publication US 2023/0212302 A1, Jul. 6, 2023
Int. Cl. C07K 16/28 (2006.01); A61P 1/00 (2006.01); A61P 35/00 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2878 (2013.01) [A61P 1/00 (2018.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); G01N 33/6863 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/732 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/70578 (2013.01)]

30 Claims

1. An anti-TNFR2 antibody or the antigen-binding fragment thereof, which comprises (i) three heavy chain complementary determining regions (CDRs) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 1, 2, and 3, respectively, and three light chain complementary determining regions (CDRs) LCDR1, LCDR2, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 4, 5, and 6, respectively; or (ii) three heavy chain complementary determining regions (CDRs) HCDR1, HCDR2, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 9, 10, and 11, respectively, and three light chain complementary determining regions (CDRs) LCDR1, LCDR2, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 12, 13, and 14, respectively.